Bacteriophage T4 Vaccine Platform for Next-Generation Influenza Vaccine Development
Open Access
- 12 October 2021
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Immunology
Abstract
Developing influenza vaccines that protect against a broad range of viruses is a global health priority. Several conserved viral proteins or domains have been identified as promising targets for such vaccine development. However, none of the targets is sufficiently immunogenic to elicit complete protection, and vaccine platforms that can enhance immunogenicity and deliver multiple antigens are desperately needed. Here, we report proof-of-concept studies for the development of next-generation influenza vaccines using the bacteriophage T4 virus-like particle (VLP) platform. Using the extracellular domain of influenza matrix protein 2 (M2e) as a readout, we demonstrate that up to ~1,281 M2e molecules can be assembled on a 120 x 86 nanometer phage capsid to generate M2e-T4 VLPs. These M2e-decorated nanoparticles, without any adjuvant, are highly immunogenic, stimulate robust humoral as well as cellular immune responses, and conferred complete protection against lethal influenza virus challenge. Potentially, additional conserved antigens could be incorporated into the M2e-T4 VLPs and mass-produced in E. coli in a short amount of time to deal with an emerging influenza pandemic.Funding Information
- National Natural Science Foundation of China-China Academy of General Technology Joint Fund for Basic Research
- Fundamental Research Funds for the Central Universities
- National Institute of Allergy and Infectious Diseases
This publication has 61 references indexed in Scilit:
- Correlates of protection against influenza infection in humans—on the path to a universal vaccine?Current Opinion in Immunology, 2013
- Mutated and Bacteriophage T4 Nanoparticle Arrayed F1-V Immunogens from Yersinia pestis as Next Generation Plague VaccinesPLoS Pathogens, 2013
- M2e-Displaying Virus-Like Particles with Associated RNA Promote T Helper 1 Type Adaptive Immunity against Influenza APLOS ONE, 2013
- Immunization with M2e-Displaying T7 Bacteriophage Nanoparticles Protects against Influenza A Virus ChallengePLOS ONE, 2012
- Efficient production of chimeric Human papillomavirus 16 L1 protein bearing the M2e influenza epitope in Nicotiana benthamiana plantsBMC Biotechnology, 2011
- COMMENTARY: Acceptable Levels of Endotoxin in Vaccine Formulations During Preclinical ResearchJournal of Pharmaceutical Sciences, 2011
- Multicomponent anthrax toxin display and delivery using bacteriophage T4Vaccine, 2007
- Assembly of Human Immunodeficiency Virus (HIV) Antigens on Bacteriophage T4: a Novel In Vitro Approach To Construct Multicomponent HIV VaccinesJournal of Virology, 2006
- Immunoinflammatory responses and fibrogenesisMedical Molecular Morphology, 2004
- Science commentary: Th1 and Th2 responses: what are they?BMJ, 2000